Bevacizumab M22136
The add to cart button will appear once you select the values above
Specifications
| inquiry |
CAS Number:
216974-75-3
Target:
VEGFR
Molecular formula:
——
Formula weight:
149 kDa
Purity:
>98% (HPLC)
Stability:
≥ 2 years
Product description:
Ipilimumab anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.Bevacizumab a humanized monoclonal antibody specifically binds to all VEGF-A isoforms with high affinity.
Note:
Research use only, not for human use.
More info:
Email info@sobekbio.com
Orders:
Email orders@sobekbio.com